Application value of circulating LncRNA in diagnosis, treatment, and prognosis of breast cancer

Funct Integr Genomics. 2023 Feb 15;23(1):61. doi: 10.1007/s10142-023-00983-8.

Abstract

Breast cancer is the malignant tumor with the highest incidence in women worldwide. It is highly heterogeneous, has a high incidence of drug resistance, recurrence, and metastasis, and is one of the malignant tumors with the highest mortality rate. The early diagnosis, treatment monitoring, and prognosis assessment of breast cancer are the key factors affecting the survival of patients. However, due to the lack of specific biomarkers, breast cancer is still an essential factor affecting women's quality of life and physical and mental health. Long non-coding RNA can regulate various genes and different signaling pathways and plays an essential role in the occurrence and development of tumors. Recent studies have found that the abnormal expression of circulating long non-coding RNA in serum, saliva, and other biological body fluids plays a significant role in early diagnosis, pathological classification, stage, therapeutic effect monitoring, and prognosis evaluation of breast cancer. This article will review the potential application value of circulating lncRNA in breast cancer.

Keywords: Breast cancer; Circulating lncRNA; Diagnosis; Prognosis; Treatment.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Biomarkers, Tumor / genetics
  • Breast Neoplasms* / diagnosis
  • Breast Neoplasms* / genetics
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Quality of Life
  • RNA, Long Noncoding* / metabolism

Substances

  • RNA, Long Noncoding
  • Biomarkers
  • Biomarkers, Tumor